Truist raised the firm’s price target on SI-Bone (SIBN) to $24 from $23 and keeps a Buy rating on the shares after its Q4 earnings beat. The company complemented its pre-announced revenue beat with gross margin upside and adjusted EBITDA about $3M ahead of consensus, while its 2026 guidance brackets estimates and should be viewed as a solid jumping-off point, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SIBN:
- SI-Bone: Durable Growth, Conservative Outlook, and Discounted Valuation Support Buy Rating
- SI-Bone: Strengthening Fundamentals, Expanding Market Catalysts, and Accelerating Growth Support Buy Rating and $23 Target
- Reiterating Buy on SI-Bone: In-Line 2025 Results, Balanced 2026 Outlook, and Smith & Nephew Alliance Drive Upside Potential
- SI-Bone: Early Profitability and 2026 Growth Catalysts Underpin Buy Rating and $22 Price Target
- Smith & Nephew signs distribution agreement with SI-Bone